Cargando…
Quantification of total and unbound cefuroxime in plasma by ultra‐performance liquid chromatography tandem mass spectrometry in a cohort of critically ill patients with hypoalbuminemia and renal failure
BACKGROUND: Pharmacokinetic studies of cefuroxime by ultra‐performance liquid chromatography tandem mass spectrometry (UPLC‐MS/MS) have been limited to measurements of total concentrations. Here, we developed a robust method for quantifying total and unbound cefuroxime concentrations using UPLC‐MS/M...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083463/ https://www.ncbi.nlm.nih.gov/pubmed/31785116 http://dx.doi.org/10.1002/jcla.23100 |
_version_ | 1783508539688353792 |
---|---|
author | van Raaij, Joost J. Mabelis, Noortje J. D. Shudofsky, Kimberly N. Meenks, Sjoerd D. le Noble, Jos L. M. L. Janssen, Paddy K. C. |
author_facet | van Raaij, Joost J. Mabelis, Noortje J. D. Shudofsky, Kimberly N. Meenks, Sjoerd D. le Noble, Jos L. M. L. Janssen, Paddy K. C. |
author_sort | van Raaij, Joost J. |
collection | PubMed |
description | BACKGROUND: Pharmacokinetic studies of cefuroxime by ultra‐performance liquid chromatography tandem mass spectrometry (UPLC‐MS/MS) have been limited to measurements of total concentrations. Here, we developed a robust method for quantifying total and unbound cefuroxime concentrations using UPLC‐MS/MS and ultrafiltration in critically ill patients with hypoalbuminemia and renal failure. METHODS: Method validation included accuracy, linearity, precision, repeatability, recovery, and limit of quantification (LOQ). Feasibility of the method was performed on samples obtained from randomly selected intensive care unit (ICU) patients. Total and unbound cefuroxime concentrations were quantified using UPLC‐MS/MS. Sampling times were categorized as trough (180‐1 min prior to administration), peak (10‐30 min after administration), mid (30‐360 min after administration), and continuous (sampling during administration). Pharmacokinetic/pharmacodynamic (PK/PD) targets were unbound cefuroxime concentrations above 4 times the minimum inhibitory concentration (32 mg/L). RESULTS: Intra‐assay and inter‐assay precision was <3%. Recovery was 99.7%‐100.3%, and LOQ was 0.1 mg/L. We included 11 patients (median age 72 years (range 54‐77). Median albumin serum concentrations and eGFR were 19 g/L (range 11‐40 g/L) and 48 mL/min/1.73 m(2) (range 7‐115 mL/min/1.73 m(2)), respectively. Median trough and mid concentrations of total cefuroxime were 22.27 mg/L (range 5.42‐54.03 mg/L) and 71.49 mg/L (range 53.87‐73.86 mg/L), and median unbound fraction was 75.42% (range 27.36%‐99.75%). Median unbound cefuroxime concentrations were 11.94 mg/L (range 3.85‐32.39 mg/L) (trough) and 55.62 mg/L (range 10.03‐62.62 mg/L) (mid). CONCLUSION: The method is precise and accurate according to ISO 15189 and within the clinical range of cefuroxime (0.5‐100 mg/L). The method was applied in ICU patients and is suitable for TDM on unbound cefuroxime concentrations. |
format | Online Article Text |
id | pubmed-7083463 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-70834632020-03-24 Quantification of total and unbound cefuroxime in plasma by ultra‐performance liquid chromatography tandem mass spectrometry in a cohort of critically ill patients with hypoalbuminemia and renal failure van Raaij, Joost J. Mabelis, Noortje J. D. Shudofsky, Kimberly N. Meenks, Sjoerd D. le Noble, Jos L. M. L. Janssen, Paddy K. C. J Clin Lab Anal Research Articles BACKGROUND: Pharmacokinetic studies of cefuroxime by ultra‐performance liquid chromatography tandem mass spectrometry (UPLC‐MS/MS) have been limited to measurements of total concentrations. Here, we developed a robust method for quantifying total and unbound cefuroxime concentrations using UPLC‐MS/MS and ultrafiltration in critically ill patients with hypoalbuminemia and renal failure. METHODS: Method validation included accuracy, linearity, precision, repeatability, recovery, and limit of quantification (LOQ). Feasibility of the method was performed on samples obtained from randomly selected intensive care unit (ICU) patients. Total and unbound cefuroxime concentrations were quantified using UPLC‐MS/MS. Sampling times were categorized as trough (180‐1 min prior to administration), peak (10‐30 min after administration), mid (30‐360 min after administration), and continuous (sampling during administration). Pharmacokinetic/pharmacodynamic (PK/PD) targets were unbound cefuroxime concentrations above 4 times the minimum inhibitory concentration (32 mg/L). RESULTS: Intra‐assay and inter‐assay precision was <3%. Recovery was 99.7%‐100.3%, and LOQ was 0.1 mg/L. We included 11 patients (median age 72 years (range 54‐77). Median albumin serum concentrations and eGFR were 19 g/L (range 11‐40 g/L) and 48 mL/min/1.73 m(2) (range 7‐115 mL/min/1.73 m(2)), respectively. Median trough and mid concentrations of total cefuroxime were 22.27 mg/L (range 5.42‐54.03 mg/L) and 71.49 mg/L (range 53.87‐73.86 mg/L), and median unbound fraction was 75.42% (range 27.36%‐99.75%). Median unbound cefuroxime concentrations were 11.94 mg/L (range 3.85‐32.39 mg/L) (trough) and 55.62 mg/L (range 10.03‐62.62 mg/L) (mid). CONCLUSION: The method is precise and accurate according to ISO 15189 and within the clinical range of cefuroxime (0.5‐100 mg/L). The method was applied in ICU patients and is suitable for TDM on unbound cefuroxime concentrations. John Wiley and Sons Inc. 2019-11-30 /pmc/articles/PMC7083463/ /pubmed/31785116 http://dx.doi.org/10.1002/jcla.23100 Text en © 2019 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles van Raaij, Joost J. Mabelis, Noortje J. D. Shudofsky, Kimberly N. Meenks, Sjoerd D. le Noble, Jos L. M. L. Janssen, Paddy K. C. Quantification of total and unbound cefuroxime in plasma by ultra‐performance liquid chromatography tandem mass spectrometry in a cohort of critically ill patients with hypoalbuminemia and renal failure |
title | Quantification of total and unbound cefuroxime in plasma by ultra‐performance liquid chromatography tandem mass spectrometry in a cohort of critically ill patients with hypoalbuminemia and renal failure |
title_full | Quantification of total and unbound cefuroxime in plasma by ultra‐performance liquid chromatography tandem mass spectrometry in a cohort of critically ill patients with hypoalbuminemia and renal failure |
title_fullStr | Quantification of total and unbound cefuroxime in plasma by ultra‐performance liquid chromatography tandem mass spectrometry in a cohort of critically ill patients with hypoalbuminemia and renal failure |
title_full_unstemmed | Quantification of total and unbound cefuroxime in plasma by ultra‐performance liquid chromatography tandem mass spectrometry in a cohort of critically ill patients with hypoalbuminemia and renal failure |
title_short | Quantification of total and unbound cefuroxime in plasma by ultra‐performance liquid chromatography tandem mass spectrometry in a cohort of critically ill patients with hypoalbuminemia and renal failure |
title_sort | quantification of total and unbound cefuroxime in plasma by ultra‐performance liquid chromatography tandem mass spectrometry in a cohort of critically ill patients with hypoalbuminemia and renal failure |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083463/ https://www.ncbi.nlm.nih.gov/pubmed/31785116 http://dx.doi.org/10.1002/jcla.23100 |
work_keys_str_mv | AT vanraaijjoostj quantificationoftotalandunboundcefuroximeinplasmabyultraperformanceliquidchromatographytandemmassspectrometryinacohortofcriticallyillpatientswithhypoalbuminemiaandrenalfailure AT mabelisnoortjejd quantificationoftotalandunboundcefuroximeinplasmabyultraperformanceliquidchromatographytandemmassspectrometryinacohortofcriticallyillpatientswithhypoalbuminemiaandrenalfailure AT shudofskykimberlyn quantificationoftotalandunboundcefuroximeinplasmabyultraperformanceliquidchromatographytandemmassspectrometryinacohortofcriticallyillpatientswithhypoalbuminemiaandrenalfailure AT meenkssjoerdd quantificationoftotalandunboundcefuroximeinplasmabyultraperformanceliquidchromatographytandemmassspectrometryinacohortofcriticallyillpatientswithhypoalbuminemiaandrenalfailure AT lenoblejoslml quantificationoftotalandunboundcefuroximeinplasmabyultraperformanceliquidchromatographytandemmassspectrometryinacohortofcriticallyillpatientswithhypoalbuminemiaandrenalfailure AT janssenpaddykc quantificationoftotalandunboundcefuroximeinplasmabyultraperformanceliquidchromatographytandemmassspectrometryinacohortofcriticallyillpatientswithhypoalbuminemiaandrenalfailure |